Portopulmonary Hypertension
📧 Sign up to get email alerts when something new happens for Portopulmonary Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Heart Problems in Children With Chronic Liver Disease
Clinical trial update describing a study on heart problems in children with chronic liver disease, currently not yet recruiting, involving c…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension
A clinical trial study investigating the genetic hallmarks of patients with congenital portosystemic shunts and portopulmonary hypertension;…
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial [Phase 3]
A multicenter Phase 3 open-label trial evaluated ambrisentan in portopulmonary hypertension; results have been posted after completion.
-
CLINICAL_TRIALS withdrawal · 2018-12-07Clinical Trial Update: Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension [Phase 4]
Phase 4 trial evaluating ambrisentan plus tadalafil for portopulmonary hypertension has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2018-11-23Clinical Trial Update: PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial [Phase 4]
A randomized Phase 4 trial evaluated macitentan for portopulmonary hypertension, with results posted in 2018.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-02-24Clinical Trial Update: A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
A clinical trial assessed the safety and efficacy of treprostinil to facilitate liver transplantation in patients with portopulmonary hypert…
-
CLINICAL_TRIALS withdrawal · 2016-06-17Clinical Trial Update: Ambrisentan for Treatment of Portopulmonary Hypertension [Phase 1, Phase 2]
The Phase 1/2 trial of Ambrisentan for portopulmonary hypertension has been withdrawn.